Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Boehringer Ingelheim
Moodys
Colorcon
Merck

Last Updated: December 9, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for AZD9291

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug AZD9291?

AZD9291 is an investigational drug.

There have been 61 clinical trials for AZD9291. The most recent clinical trial was a Phase 2 trial, which was initiated on August 1st 2014.

The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, and Carcinoma. The leading clinical trial sponsors are AstraZeneca, National Cancer Institute (NCI), and Parexel.

There are eleven US patents protecting this investigational drug and one hundred and seventy-five international patents.

Recent Clinical Trials for AZD9291
TitleSponsorPhase
AZD9291 (Osimertinib) With or Without Bevacizumab as First-Treatment for Patients With EGFR-Mutant Lung CancerNational Cancer Institute (NCI)Phase 3
Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal MetastasisNanchang UniversityPhase 2
Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal MetastasisSecond Affiliated Hospital of Nanchang UniversityPhase 2

See all AZD9291 clinical trials

Clinical Trial Summary for AZD9291

Top disease conditions for AZD9291
Top clinical trial sponsors for AZD9291

See all AZD9291 clinical trials

US Patents for AZD9291

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
AZD9291   Start Trial 2-(2,4,5-substituted-anilino)pyrimidine compounds AstraZeneca AB (Sodertalje, SE)   Start Trial
AZD9291   Start Trial AZD9291 intermediate and preparation method therefor SUZHOU MIRACPHARMA TECHNOLOGY CO., LTD. (Suzhou, CN)   Start Trial
AZD9291   Start Trial Pharmaceutical compositions comprising AZD9291 AstraZeneca AB (Sodertalje, SE)   Start Trial
AZD9291   Start Trial Heteroaryl compounds for kinase inhibition ARIAD PHARMACEUTICALS, INC. (Cambridge, MA)   Start Trial
AZD9291   Start Trial Pyrimidines as EGFR inhibitors and methods of treating disorders Dana-Farber Cancer Institute, Inc. (Boston, MA)   Start Trial
AZD9291   Start Trial 2-(2,4,5-substituted-anilino) pyrimidine compounds AstraZeneca AB (Sodertalje, SE)   Start Trial
AZD9291   Start Trial 2-(2,4,5-substituted-anilino)pyrimidine compounds ASTRAZENECA AB (SE)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for AZD9291

Drugname Country Document Number Estimated Expiration Related US Patent
AZD9291 Argentina 087336 2031-07-27   Start Trial
AZD9291 Australia 2012288626 2031-07-27   Start Trial
AZD9291 Brazil 112014001768 2031-07-27   Start Trial
AZD9291 Brazil 122014026094 2031-07-27   Start Trial
AZD9291 Brazil 122014026114 2031-07-27   Start Trial
AZD9291 Brazil 122014026150 2031-07-27   Start Trial
AZD9291 Canada 2843109 2031-07-27   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Medtronic
Colorcon
Moodys
Boehringer Ingelheim
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.